Feb. 3 at 6:56 PM
$MXCT No position here. why down so much?
Significant Revenue Misses & Lowered Guidance: MaxCyte reported Q3 2025 revenue of
$6.8 million, down from
$8.2 million in the same quarter of 2024, missing expectations. The company also revised its 2025 core revenue guidance to be "flat to down 10%" due to challenges in the operating environment.
Plummeting License Revenue (SPL): Strategic Platform License (SPL) revenue, a key metric for the company, dropped 99% to only
$83,000 in Q4 2024 compared to
$8.5 million in the previous year.
Customer Pipeline Consolidation: The company has cited "customer inventory management" and a "reprioritization and consolidation of customer pipelines" as reasons for decreased demand in the cell and gene therapy (CGT) market.
Operational Costs and Restructuring: Despite a high gross margin, MaxCyte has been undergoing significant workforce reductions for cost savings. The costs associated with acquiring SeQure Dx also impacted their cash position.
